The business of life sciences came into sharp focus after the pandemic highlighted the effectiveness of mRNA vaccines in protecting people against COVID. But what exactly is life sciences and is the recent market weakness a threat to future innovation — or an opportunity? In the latest episode of Exchanges at Goldman Sachs, Amit Sinha, head of Life Sciences Investing in Goldman Sachs Asset Management, discusses the evolution of life sciences and how investors are approaching the risks and opportunities within the biotechnology sector.
Ryan Watts, CEO and co-founder of Denali Therapeutics, discusses his company’s mission, the progress it has made in the battle against neurodegenerative diseases, and how his personal experience of losing his mother to Alzheimer’s has underscored the urgency to develop cutting-edge therapies in this field.
Amid many concerns heading into 2020, the event that no one expected was the outbreak of COVID-19—a coronavirus that first emerged in the populous city of Wuhan, China, and which is now proving to be both more infectious and virulent than the common flu. As China attempts to restart its economy after an unprecedented lockdown, the virus continues to spread globally, and data on the sizeable economic fallout starts to trickle in, coronavirus is Top of Mind.
In this episode, we dig into what may be the most important issue of our time: climate change. On the heels of a climate-focused World Economic Forum in Davos, the unveiling of Europe’s new Green Deal, and increased attention on climate change by the world’s largest asset managers and banks, climate change is undoubtedly Top of Mind.
Extreme ultraviolet lithography is poised to help power the next generation of technologies and impact the $50bn global semiconductor equipment market. Goldman Sachs Research explains how this technology will allow the production of more powerful chips at lower cost. Watch Video
Climate change is a global issue, but cities—with their high population densities and robust economic activity—are likely to find themselves on the frontlines of adaptation. Goldman Sachs’ Global Markets Institute explains how making urban centers resilient to this growing challenge could drive the largest infrastructure buildout in history. Watch Video
The “fourth wave in cancer treatment” could be emerging from an approach called chromatin biology. Paul Choi of Goldman Sachs Research explains the science behind chromatin-based approaches and their potential to treat 20%-30% of cancers. Watch Video
Tim Urban, co-founder of the blog Wait But Why, spends his days writing about what he calls “this magical world of the future.” He explains everything from space travel to artificial intelligence to the thinking of leaders like Elon Musk. In this discussion, Urban tackles some of the toughest issues he’s written about – from technology to politics. Watch Video
In this discussion, Satya Nadella, CEO of Microsoft and author of the recently published Hit Refresh, discusses his vision for the future of Microsoft and the technologies that will most impact our economy and society in the next several years, including AI. Watch Video
Juan Enriquez, co-founder and managing director of Excel Venture Management, discusses how humans are reshaping the path of evolution and why "there's no better time to be alive than today, except in two generations" in this Talks at GS session at the 2017 Goldman Sachs EMEA CEO Forum in London. Watch Video
Dan Huttenlocher, founding dean and vice provost of Cornell Tech, discusses how the school is creating a new model for higher education and gives his perspectives on the most important technology trends on the horizon, from automation to artificial intelligence, and the impact they will have across industries. Watch Video
At Goldman Sachs' Builders + Innovators Summit, Stanford University neuroscientist David Eagleman discusses why the power of the human brain makes the human species so unique – it has to do with human creativity. Watch Video
In this discussion at Goldman Sachs’ Builders + Innovators Summit, Nick Leschly, the CEO of Bluebird Bio, discusses the progress his company has made in the field of gene therapy to treat and cure disease, from combatting sickle cell disease to progress in the fight against rare forms of cancer, and why understanding our genetics is key to the next generation of groundbreaking medical advancements. Watch Video